Abstract
We have previously reported that the injection of a newly developed chelating agent, catechol-3, 6-bis (methyleneiminodiacetic acid) (CBMIDA), removes plutonium particularly from the bones, more effectively than DTPA in rats. Nevertheless, the removed plutonium is later redistributed to the kidneys, an undesirable phenomenon, in chelation therapy. Therefore, it was considered of interest to survey the effects of four new analogues of CBMIDA (C-I-C-IV) on the removal of plutonium in rats and compared with the CBMIDA. After the intravenous injection of plutonium, CBMIDA and its analogues were administered daily, for 2 weeks by intraperitoneal injection or by oral administration. The gathered data indicated that the intraperitoneal administration of two analogues, C-II and C-III significantly decreased the amount of plutonium in the bones and liver (p<0.01), and that in the spleen, testis and kidney were also reduced. In conclusion, the results indicate that among the tested agents, these two chelating agents present useful characteristics for the chelation therapy in individuals contaminated with plutonium.
